The 2026-2027 Board of Directors nomination window is now open! The AST is currently accepting nominations for President, Treasurer, and three Councilors-at-Large. The election will begin in April 2026, and newly elected board members will begin their terms on June 22, 2026, following the AST Town Hall at the American Transplant Congress.

On behalf of the AST, the European Society for Organ Transplantation (ESOT), and The Transplantation Society (TTS), we are excited to invite you to attend the International Transplantation Science Meeting 2025. 

 

ITS 2025 marks the fourth tri-society event in this global collaboration, bringing together top experts, early-career researchers, and transplant professionals worldwide. This meeting offers an exciting forum to explore cutting-edge basic and translational science in and beyond the field of transplantation.

As the 2025 AST membership year begins to close, don't forget to renew your membership and reaffirm your commitment to the AST. Renewal invoices were distributed via email and are due December 31, 2025. If you didn't receive your email, you may log in anytime to your AST member account. Don't miss out on all future AST educational, networking, advocacy, and research efforts!

The Donation Derby is back — and your Community of Practice (COP) needs your support! Every gift you make helps fund your COP’s initiatives and projects and brings them one step closer to victory. Rally behind your COP, make a donation, and help them race to the top!

Join us at CEoT 2026, a three-day meeting focused on advancing transplantation science, clinical practice, and patient outcomes. This meeting will explore the future of transplantation across all organ types, highlighting innovation, equity, and lifelong patient care. Hear from leading experts and engage in interactive breakout sessions across specialties, focusing on emerging technologies, allocation strategies, and the changing landscape of organ disease.

The AST is now accepting applications for its 2026 Career Development Grant cycle! These grants promote the careers of early-career investigators whose research relates to solid organ transplantation (and/or immunology relating to solid organ transplant).

The AST developed a survey aimed at soliciting your perspectives on legislative and regulatory issues that significantly influence both patient care and professional practice. Our goal is to establish a platform for our membership to share their invaluable ideas and perspectives and actively engage with the Public Policy Committee and AST leadership. We look forward to your input as we navigate the dynamics of our ever-evolving landscape of transplant care and practice.

Source: American Journal of Transplantation
In 2020, the Centers for Medicare and Medicaid Services updated the organ procurement organization (OPO) conditions for coverage, redefining deceased donor potential as all inpatient deaths among patients aged ≤75 years with a primary cause of death consistent with organ donation, also called CALC (cause, age [years], and location consistent with donation). This study evaluates CALC performance metrics using 2018-2021 data from the Centers for Disease Control (CDC) mortality data (currently used by the Centers for Medicare and Medicaid Services) and the Agency for Healthcare Research and Quality’s State Inpatient Databases. We analyzed yearly performance variability, compared data sources, and examined the impact of CALC vs CALC-adjusted, which excludes donors with potential contraindications. 

Source: American Journal of Transplantation
Maribavir has demonstrated promising efficacy in treating refractory cytomegalovirus (CMV) infections among solid organ transplant recipients; however, factors influencing favourable outcomes remain uncertain. We conducted a retrospective cohort study that involved 88 kidney transplant recipients (KTRs) from 22 transplantation centers, all of whom had refractory CMV infections treated with maribavir (63 with ganciclovir resistance mutations and 25 without). CMV clearance at week 8 was achieved in 45 KTRs (51.1%). 

Source: LWW Journals
Ischemia/reperfusion injury is an unavoidable consequence of kidney transplantation, yet the characteristics of the immediate immune response after reperfusion and its impact on transplant outcomes remain poorly characterized in the clinical setting.